Fulcrum Therapeutics Inc. (FULC) remains in focus as it advances multiple programs targeting genetically defined rare diseases. The company's lead candidate, pociredir, continues to progress through the Phase 1b PIONEER trial in sickle cell disease or SCD, with the 20 mg dose cohort currently underway.
Fulcrum has confirmed plans to share clinical data from this cohort by the end of 2025, following promising results from the earlier 12 mg group, which showed robust increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.